drugset

drugset / Trial / NCT05162066

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

NCT05162066 ↗

Phase 2 Terminated 2 enrolled BioCryst Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

Timeline

Start: 2022-02-18
Primary completion: 2022-09-23
Completion: 2022-09-23

Publications

Lin J, Radhakrishnan J. What Are Baskets, Umbrellas, and Platforms Doing in Nephrology Clinical Trials? J Am Soc Nephrol. 2025 Feb 3;36(8):1652-1654. doi: 10.1681/ASN.0000000648. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BCX9930	Unknown	400 mg	Oral

Indications